JNJ 56022473

Drug Profile

JNJ 56022473

Alternative Names: CSL 362AML; CSL-362; IL-13 MAb - CSL; JNJ 473; JNJ56022473; Talacotuzumab

Latest Information Update: 10 Jan 2017

Price : $50

At a glance

  • Originator CSL
  • Developer CSL; Janssen Biotech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Interleukin-3-receptor-alpha-subunit-antagonists; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes
  • Preclinical Systemic lupus erythematosus

Most Recent Events

  • 04 Jan 2017 Janssen Research & Development plans a proof-of-concept phase II trial for Myelodysplastic syndromes (Monotherapy, Second-line therapy or greater) in USA, France, Netherlands, Belgium and Spain (IV, Infusion) (NCT03011034)
  • 12 Dec 2016 Phase-II clinical trials in Acute myeloid leukaemia (Monotherapy, Second-line therapy or greater) in Germany (IV) (NCT02992860)
  • 12 Dec 2016 Phase-II clinical trials in Myelodysplastic syndromes (Monotherapy, Second-line therapy or greater) in Germany (IV-infusion) (NCT02992860)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top